Molecular mimicry between virus and host and its implications for dengue disease pathogenesis

Experimental Biology and Medicine

Volumn 236, Issue 5, 2011, Pages 515-523

  Lin, Yee Shin ^a   Yeh, Trai Ming ^a   Lin, Chiou Feng ^a   Wan, Shu Wen ^a   Chuang, Yung Chun ^a   Hsu, Tan Kuei ^a   Liu, Hsiao Sheng ^a   Liu, Ching Chuan ^a   Anderson, Robert ^b   Lei, Huan Yao ^a  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Autoimmunity; Coagulatory molecules; Dengue virus; Endothelial cells; Molecular mimicry; Platelets

Indexed keywords

AUTOANTIBODY; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 9; EPITOPE; FIBRIN; FIBRINOGEN; NONSTRUCTURAL PROTEIN 1; PLASMINOGEN; PROTHROMBIN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TISSUE PLASMINOGEN ACTIVATOR; VIRUS ANTIBODY;

AMINO ACID SEQUENCE; ANTIBODY DETECTION; AUTOIMMUNITY; BLOOD CLOTTING; BYSTANDER EFFECT; CARBOXY TERMINAL SEQUENCE; CELL DAMAGE; COXSACKIE VIRUS; CROSS REACTION; CRYOGLOBULINEMIA; DENGUE; DENGUE VIRUS; ENDOTHELIUM CELL; EPSTEIN BARR VIRUS; FIBRIN FORMATION; HEPATITIS C VIRUS; HERPES SIMPLEX VIRUS; HUMAN; HUMAN CYTOMEGALOVIRUS; HUMAN PARVOVIRUS B19; IMMUNOPATHOGENESIS; INFECTION; INSULIN DEPENDENCE; MOLECULAR MECHANICS; MOLECULAR MIMICRY; MULTIPLE SCLEROSIS; MYOCARDITIS; NONHUMAN; POLYCLONAL ACTIVATION; PROTEIN TARGETING; PROTEOMICS; REVIEW; RHEUMATOID ARTHRITIS; RUBELLA VIRUS; SEQUENCE ANALYSIS; SEQUENCE HOMOLOGY; SEROLOGY; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBIN TIME; THROMBOCYTE; VIRUS CELL INTERACTION;

AMINO ACID SEQUENCE; AUTOIMMUNITY; BLOOD PLATELETS; DENGUE; ENDOTHELIAL CELLS; HOST-PATHOGEN INTERACTIONS; HUMANS; MODELS, BIOLOGICAL; MOLECULAR MIMICRY; MOLECULAR SEQUENCE DATA; VIRAL PROTEINS;

DENGUE VIRUS;

EID: 79958853212     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: 10.1258/ebm.2011.010339     Document Type: Review

References (88)

1. Harel M, Shoenfeld Y. Predicting and preventing autoimmunity, myth or reality? Ann NY Acad Sci 2006;1069:322-345
2. Sfriso P, Ghirardello A, Botsios C, Tonon M, Zen M, Bassi N, Bassetto F, Doria A. Infections and autoimmunity: the multifaceted relationship. J Leukoc Biol 2009;87:385-395
3. Doria A, Canova M, Tonon M, Zen M, Rampudda E, Bassi N, Atzeni F, Zampieri S, Ghirardello A. Infections as triggers and complications of systemic lupus erythematosus. Autoimmun Rev 2008;8:24-28
4. Randone SB, Guiducci S, Cerinic MM. Systemic sclerosis and infections. Autoimmun Rev 2008;8:36-40
5. Vreugdenhil GR, Batstra MR, Aanstoot HJ, Melchers WJ, Galama JM. Analysis of antibody responses against coxsackie virus B4 protein 2C and the diabetes autoantigen GAD65. J Med Virol 1999;59:256-261
6. Stathopoulou EA, Routsias JG, Stea EA, Moutsopoulos HM, Tzioufas AG. Cross-reaction between antibodies to the major epitope of Ro60 kD autoantigen and a homologous peptide of Coxsackie virus 2B protein. Clin Exp Immunol 2005;141:148-154
7. Ou D, Mitchell LA, Metzger DL, Gillam S, Tingle AJ. Cross-reactive rubella virus and glutamic acid decarboxylase (65 and 67) protein determinants recognised by T cells of patients with type I diabetes mellitus. Diabetologia 2000;43:750-762
8. Toussirot E, Roudier J. Epstein-Barr virus in autoimmune diseases. Best Pract Res Clin Rheumatol 2008;22:883-896
9. Lunemann JD, Jelcic I, Roberts S, Lutterotti A, Tackenberg B, Martin R, Munz C. cells from patients with multiple sclerosis cross react with myelin antigens and co-produce IFN-g and IL-2. J Exp Med 2008;205:1763-1773
10. McClain MT, Heinlen LD, Dennis GJ, Roebuck J, Harley JB, James JA. Early events in lupus humoral autoimmunity suggest initiation through molecular mimicry. Nat Med 2005;11:85-89
11. Neidhart M, Kuchen S, Distler O, Bruhlmann P, Michel BA, Gay RE, Gay S. Increased serum levels of antibodies against human cytomegalovirus and prevalence of autoantibodies in systemic sclerosis. Arthritis Rheum 1999;42:389-392
12. Zhao ZS, Granucci F, Yeh L, Schaffer PA, Cantor H. Molecular mimicry by herpes simplex virus-type 1: autoimmune disease after viral infection. Science 1998;279:1344-1347
13. Muryoi T, Kasturi KN, Kafina MJ, Cram DS, Harrison LC, Sasaki T, Bona CA. Antitopoisomerase I monoclonal autoantibodies from scleroderma patients and tight skin mouse interact with similar epitopes. J Exp Med 1992;175:1103-1109
14. Lunardi C, Tinazzi E, Bason C, Dolcino M, Corrocher R, Puccetti A. Human parvovirus B19 infection and autoimmunity. Autoimmun Rev 2008;8:116-20
15. Halstead SB. Dengue. Lancet 2007;370:1644-1652
16. Kyle JL, Harris E. Global spread and persistence of dengue. Annu Rev Microbiol 2008;62:71-792
17. Gubler DJ. Dengue and dengue hemorrhagic fever. Clin Microbiol Rev 1998;11:480-496
18. Whitehead SS, Blaney JE, Durbin AP, Murphy BR. Prospects for a dengue virus vaccine. Nat Rev Microbiol 2007;5:518-528
19. Lei HY, Yeh TM, Liu HS, Lin YS, Chen SH, Liu CC. Immunopathogenesis of dengue virus infection. J Biomed Sci 2001;8:377-388
20. Green S, Rothman A. Immunopathological mechanisms in dengue and dengue hemorrhagic fever. Curr Opin Infect Dis 2006;19:429-436
21. Clyde K, Kyle JL, Harris E. Recent advances in deciphering viral and host determinants of dengue virus replication and pathogenesis. J Virol 2006;80:11418-11431
22. Lin CF, Wan SW, Cheng HJ, Lei HY, Lin YS. Autoimmune pathogenesis in dengue virus infection. Viral Immunol 2006;19:127-132
23. Pang T, Cardosa MJ, Guzman MG. Of cascades and perfect storms: the immunopathogenesis of dengue haemorrhagic fever-dengue shock syndrome (DHF/DSS). Immunol Cell Biol 2007;85:43-45
24. Halstead SB. Pathogenesis of dengue: challenges to molecular biology. Science 1988;239:476-481
25. Halstead SB. Neutralization and antibody-dependent enhancement of dengue viruses. Adv Virus Res 2003;60:421-467
26. Goncalvez AP, Engle RE, St Claire M, Purcell RH, Lai CJ. Monoclonal antibody-mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention. Proc Natl Acad Sci USA 2007;104:9422-9427
27. Boonnak K, Slike BM, Burgess TH, Mason RM, Wu SJ, Sun P, Porter K, Rudiman IF, Yuwono D, Puthavathana P, Marovich MA. Role of dendritic cells in antibody-dependent enhancement of dengue virus infection. J Virol 2008;82:3939-3951
28. Lin CC, Huang YH, Shu PY, Wu HS, Lin YS, Yeh TM, Liu HS, Liu CC, Lei HY. Characteristic of dengue disease in Taiwan: 2002-2007. Am J Trop Med Hyg 2010;82:731-739
29. Lei HY, Huang KJ, Lin YS, Yeh TM, Liu HS, Liu CC. Immunopathogenesis of dengue hemorrhagic fever. Am J Infect Dis 2008;4:1-9
30. Garcia G, Gonzalez N, Perez AB, Sierra B, Aguirre E, Rizo D, Izquierdo A, Sanchez L, Diaz D, Lezcay M, Pacheco B, Hirayama K, Guzman MG. Long-term persistence of clinical symptoms in dengue-infected persons and its association with immunological disorders. Int J Infect Dis 2011;15:e38-e43
31. Rothman AL, Ennis FA. Immunopathogenesis of dengue hemorrhagic fever. Virology 1999;257:1-6
32. Basu A, Chaturvedi UC. Vascular endothelium: the battlefield of dengue viruses. FEMS Immunol Med Microbiol 2008;53:287-929
33. Anderson R, Wang S, Osiowy C, Issekutz AC. Activation of endothelial cells via antibody-enhanced dengue virus infection of peripherial blood monocytes. J Virol 1997;71:4226-4232
34. Avirutnan P, Malasit P, Seliger B, Bhakdi S, Husmann M. Dengue virus infection of human endothelial cells leads to chemokine production, complement activation, and apoptosis. J Immunol 1998;161:6338-6346
35. Falconar AK. The dengue virus nonstructural-1 protein (NS1) generates antibodies to common epitopes on human blood clotting, integrin/adhesin proteins and binds to human endothelial cells: potential implications in haemorrhagic fever pathogenesis. Arch Virol 1997;142:897-9816
36. Lin CF, Lei HY, Shiau AL, Liu HS, Yeh TM, Chen SH, Liu CC, Chiu SC, Lin YS. Endothelial cell apoptosis induced by antibodies against dengue virus nonstructural protein 1 via production of nitric oxide. J Immunol 2002;169:657-664
37. Lin CF, Lei HY, Shiau AL, Liu CC, Liu HS, Yeh TM, Chen SH, Lin YS. Antibodies from dengue patient sera cross-react with endothelial cells and induce damage. J Med Virol 2003;69:82-90
38. Lin YS, Lin CF, Lei HY, Liu HS, Yeh TM, Chen SH, Liu CC. Antibody-mediated endothelial cell damage via nitric oxide. Curr Pharm Design 2004;10:213-221
39. Lin CF, Chiu SC, Hsiao YL, Wan SW, Lei HY, Shiau AL, Liu HS, Yeh TM, Chen SH, Liu CC, Lin YS. Expression of cytokine, chemokine, and adhesion molecules during endothelial cell activation induced by antibodies against dengue virus nonstructural protein 1. J Immunol 2005;174:395-3403
40. Lin CF, Wan SW, Chen MC, Lin SC, Cheng CC, Chiu SC, Hsiao YL, Lei HY, Liu HS, Yeh TM, Lin YS. Liver injury caused by antibodies against dengue virus nonstructural protein 1 in a murine model. Lab Invest 2008;88:1079-1089
41. Lin CF, Lei HY, Liu CC, Liu HS, Yeh TM, Wang ST, Yang TI, Sheu FC, Kuo CF, Lin YS. Generation of IgM anti-platelet autoantibody in dengue patients. J Med Virol 2001;63:143-149
42. Lin CF, Lei HY, Liu CC, Liu HS, Yeh TM, Anderson R, Lin YS. Patient and mouse antibodies against dengue virus nonstructural protein 1 cross-react with platelets and cause their dysfunction or depletion. Am J Infect Dis 2008;4:69-75
43. Huang KJ, Li SY, Chen SC, Liu HS, Lin YS, Yeh TM, Liu CC, Lei HY. Manifestation of thrombocytopenia in dingue-2-virus-infected mice. J Gen Virol 2000;81:2177-2182
44. Chen MC, Lin CF, Lei HY, Lin SC, Liu HS, Yeh TM, Anderson R, Lin YS. Deletion of the C-terminal region of dengue virus nonstructural protein 1 (NS1) abolishes anti-NS1-mediated platelet dysfunction and bleeding tendency. J Immunol 2009;183:1797-1803
45. Rose NR, Bona C. Defining criteria for autoimmune diseases (Witebsky's postulates revisited). Immunol Today 1993;14:426-430
46. Cheng HJ, Lin CF, Lei HY, Liu HS, Yeh TM, Luo YH, Lin YS. Proteomic analysis of endothelial cell autoantigens recognized by anti-dengue virus nonstructural protein 1 antibodies. Exp Biol Med 2009;234:63-73
47. Huang KJ, Yang YC, Lin YS, Huang JH, Liu HS, Yeh TM, Chen SH, Liu CC, Lei HY. The dual-specific binding of dengue virus and target cells for the antibody-dependent enhancement of dengue virus infection. J Immunol 2006;176:2825-2832
48. Cheng HJ, Lei HY, Lin CF, Luo YH, Wan SW, Liu HS, Yeh TM, Lin YS. Anti-dengue virus nonstructural protein 1 antibodies recognize protein disulfide isomerase on platelets and inhibit platelet aggregation. Mol Immunol 2009;47:398-406
49. Wan SW, Lin CF, Chen MC, Lei HY, Liu HS, Yeh TM, Liu CC, Lin YS. C-terminal region of dengue virus nonstructural protein 1 is involved in endothelial cell cross-reactivity via molecular mimicry. Am J Infect Dis 2008;4:85-91
50. Colman RW, Marder VJ, Clowes AW, George JN, Goldhaber SZ. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. PA: Lippincott Williams & Wilkins, 2006
51. Davie EW, Fujikawa K, Kisiel W. The coagulation cascade: initiation, maintenance, and regulation. Biochemistry 1991;30:10363-103
52. Hwang KK, Grossman JM, Visvanathan S, Chukwuocha RU, Woods L Jr, Le DT, Hahn BH, Chen PP. Identification of anti-thrombin antibodies in the antiphospholipid syndrome that interfere with the inactivation of thrombin by antithrombin. J Immunol 2001;167:7192-7198
53. Lin WS, Chen PC, Yang CD, Cho E, Hahn BH, Grossman J, Hwang KK, Chen PP. Some antiphospholipid antibodies recognize conformational epitopes shared by beta2-glycoprotein I and the homologous catalytic domains of several serine proteases. Arthritis Rheum 2007;56:1638-1647
54. Yang CD, Hwang KK, Yan W, Gallagher K, FitzGerald J, Grossman JM, Hahn BH, Chen PP. Identification of anti-plasmin antibodies in the antiphospholipid syndrome that inhibit degradation of fibrin. J Immunol 2004;172:5765-5773
55. Yang YH, Chien D, Wu M, FitzGerald J, Grossman JM, Hahn BH, Hwang KK, Chen PP. Novel autoantibodies against the activated coagulation factor IX (FIXa) in the antiphospholipid syndrome that interpose the FIXa regulation by antithrombin. J Immunol 2009;182:1674-1680
56. Chen WH, Kao YF, Liu JS. An increase of blood anti-beta2-glycoprotein I antibody in Japanese encephalitis associated with cerebral ischemia. Blood Coagul Fibrinolysis 2005;16:55-59
57. Sene D, Piette JC, Cacoub P. Antiphospholipid antibodies, antiphospholipid syndrome and infections. Autoimmun Rev 2008;7:272-277
58. Oldstone MB. Molecular mimicry and immune-mediated diseases. FASEB J 1998;12:1255-1265
59. Oldstone MB. Molecular mimicry, microbial infection, and autoimmune disease: evolution of the concept. Curr Top Microbiol Immunol 2005;296:1-17
60. Wang X, Lin X, Loy JA, Tang J, Zhang XC. Crystal structure of the catalytic domain of human plasmin complexed with streptokinase. Science 1998;281:1662-165
61. Cosgriff TM. 1989. Viruses and hemostasis. Rev Infect Dis 1998;11 (Suppl. 4):S672-8S68
62. Chen JP, Cosgriff TM. Hemorrhagic fever virus-induced changes in hemostasis and vascular biology. Blood Coagul Fibrinolysis 2000;11:461-483
63. Henchal EA, Putnak JR. The dengue viruses. Clin Microbiol Rev 1990;3:376-396
64. Huang YH, Liu CC, Wang ST, Lei HY, Liu HL, Lin YS, Wu HL, Yeh TM. Activation of coagulation and fibrinolysis during dengue virus infection. J Med Virol 2001;63:247-251
65. Wills BA, Oragui EE, Stephens AC, Daramola OA, Dung NM, Loan HT, Chau NV, Chambers M, Stepniewska K, Farrar JJ, Levin M. Coagulation abnormalities in dengue hemorrhagic fever: serial investigations in 167 Vietnamese children with dengue shock syndrome. Clin Infect Dis 2002;35:277-285
66. Mairuhu AT, Mac Gillavry MR, Setiati TE, Soemantri A, ten Cate H, Brandjes DP, van Gorp EC. Is clinical outcome of dengue-virus infections influenced by coagulation and fibrinolysis? A critical review of the evidence. Lancet Infect Dis 2003;3:33-41
67. Sun DS, King CC, Huang HS, Shih YL, Lee CC, Tsai WJ, Yu CC, Chang HH. Antiplatelet autoantibodies elicited by dengue virus non-structural protein 1 cause thrombocytopenia and mortality in mice. J Thromb Haemost 2007;5:2291-2299
68. Chen Y, Maguire T, Hileman RE, Fromm JR, Esko JD, Linhardt RJ, Marks RM. Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate. Nat Med 1997;3:866-871
69. Germi R, Crance JM, Garin D, Guimet J, Lortat-Jacob H, Ruigrok RW, Zarski JP, Drouet E. Heparan sulfate-mediated binding of infectious dengue virus type 2 and yellow fever virus. Virology 2002;292:162-168
70. Lin YL, Lei HY, Lin YS, Yeh TM, Chen SH, Liu HS. Heparin inhibits dengue-2 virus infection of five human liver cell lines. Antiviral Res 2002;56:93-96
71. Marks RM, Lu H, Sundaresan R, Toida T, Suzuki A, Imanari T, Hernaiz MJ, Linhardt RJ. Probing the interaction of dengue virus envelope protein with heparin: assessment of glycosaminoglycan-derived inhibitors. J Med Chem 2001;44:2178-2187
72. Markoff LJ, Innis BL, Houghten R, Henchal LS. Development of cross-reactive antibodies to plasminogen during the immune response to dengue virus infection. J Infect Dis 1991;164:294-301
73. Huang YH, Chang BI, Lei HY, Liu HS, Liu CC, Wu HL, Yeh TM. Antibodies against dengue virus E protein peptide bind to human plasminogen and inhibit plasmin activity. Clin Exp Immunol 1997;110:35-40
74. Chungue E, Poli L, Roche C, Gestas P, Glaziou P, Markoff LJ. Correlation between detection of plasminogen cross-reactive antibodies and hemorrhage in dengue virus infection. J Infect Dis 1994;170:1304-1307
75. Chen LC, Lei HY, Liu CC, Shiesh SC, Chen SH, Liu HS, Lin YS, Wang ST, Shyu HW, Yeh TM. Correlation of serum levels of macrophage migration inhibitory factor with disease severity and clinical outcome in dengue patients. Am J Trop Med Hyg 2006;74:142-147
76. Lei HY. Transient hemophagocytic activity in dengue immunopathogenesis. J Formos Med Assoc 2009;108:595-598
77. Lei HY. The challenge and opportunity for the dengue vaccine development. In: Lei H-Y, ed. Dengue Disease. Chapter 21. Kerala, India: Research Signpost, 2008
78. Webster DP, Farrar J, Rowland-Jones S. Progress towards a dengue vaccine. Lancet Infect Dis 2009;9:678-687
79. Swaminathan S, Batra G, Khanna N. Dengue vaccines: state of the art. Expert Opin Ther Patents 2010;20:819-835
80. Badorff C, Lee GH, Lamphear BJ, Martone ME, Campbell KP, Rhoads RE, Knowlton KU. Enteroviral protease 2A cleaves dystrophin: evidence of cytoskeletal disruption in an acquired cardiomyopathy. Nat Med 1999;5:320-36
81. Luo H, Zhang J, Dastvan F, Yanagawa B, Reidy MA, Zhang HM, Yang D, Wilson JE, McManus BM. Ubiquitin-dependent proteolysis of cyclin D1 is associated with coxsackievirus-induced cell growth arrest. JVirol 2003;77:1-9
82. Ferri C, Antonelli A, Mascia MT, Sebastiani M, Fallahi P, Ferrari D, Pileri SA, Zignego AL. HCV-related autoimmune and neoplastic disorders: the HCV syndrome. Dig Liver Dis 2007;39 (Suppl. 1):S13-S21
83. Agmon-Levin N, Ram M, Barzilai O, Porat-Katz BS, Parikman R, Selmi C, Gershwin ME, Anaya JM, Youinou P, Bizzaro N, Tincani A, Tzioufas AG, Cervera R, Stojanovich L, Martin J, Gonzalez-Gay MA, Valentini G, Blank M, SanMarco M, Rozman B, Bombardieri S, De Vita S, Shoenfeld Y. Prevalence of hepatitis C serum antibody in autoimmune diseases. J Autoimmun 2009;32:261-266
84. Antonelli A, Ferri C, Ferrari SM, Colaci M, Fallahi P. Immunopathogenesis of HCV-related endocrine manifestations in chronic hepatitis and mixed cryoglobulinemia. Autoimmun Rev 2008;8:18-23
85. + regulatory T-cell deficiency in patients with hepatitis C-mixed cryoglobulinemia vasculitis. Blood 2004;103:3428-430
86. Varani S, Frascaroli G, Landini MP, Soderberg-Naucler C. Human cytomegalovirus targets different subsets of antigen-presenting cells with pathological consequences for host immunity: implications for immunosuppression, chronic inflammation and autoimmunity. Rev Med Virol 2009;19:131-145
87. Su BY, Su CY, Yu SF, Chen CJ. Incidental discovery of high systemic lupus erythematosus disease activity associated with cytomegalovirus viral activity. Med Microbiol Immunol 2007;196:165-170
88. Meyer O. Parvovirus B19 and autoimmune diseases. Jt Bone Spine 2003;70:6-11